No Data
Tus-pharmaceutical group (000590.SZ): Intends to increase the capital of the traditional chinese medicine company by 25 million yuan
Golden Union announced on November 22 that tus-pharmaceutical group (000590.SZ) plans to increase the capital of its wholly-owned subsidiary, Guhan Traditional Chinese Medicine Co., Ltd. (hereinafter referred to as the "Traditional Chinese Medicine Company"), by RMB 25 million with its own funds. After the capital increase, the registered capital of the Traditional Chinese Medicine Company will increase to RMB 160 million, and the company will still hold 100% equity of the Traditional Chinese Medicine Company.
Tus-Pharmaceutical Group Co., Ltd.'s (SZSE:000590) Shares Climb 37% But Its Business Is Yet to Catch Up
Enlightenment Pharmaceutical: Report for the third quarter of 2024
tus-pharmaceutical group (000590.SZ): a net loss of 28.4545 million yuan in the first three quarters.
On October 29, Gelonhui reported that Tus-Pharmaceutical Group (000590.SZ) announced its third quarter report for 2024, with the company achieving revenue of 0.216 billion yuan in the first three quarters, a year-on-year decrease of 21.26%; the net income attributable to shareholders of the listed company was -28.4545 million yuan; net income attributable to shareholders of the listed company excluding non-recurring gains and losses was -31.8838 million yuan; basic earnings per share was -0.1188 yuan.
Tus-pharmaceutical group (000590.SZ): guangdong Xiantong Pharma currently has no products for the treatment of dengue fever.
According to the investor interaction platform, tus-pharmaceutical group (000590.SZ) stated that its wholly-owned subsidiary, Guangdong Xiantong Pharmaceutical Co., Ltd. currently has no products for the treatment of dengue fever.
Tus-pharmaceutical group (000590.SZ): Received a notice of termination of equity transfer from Ming Shi Pharmaceutical shareholder.
On September 4th, Gelonhui reported that Tus-Pharmaceutical Group (000590.SZ) announced that on September 3rd, 2024, the company received a notification letter from Wuhan Minshi Pharmaceutical Co., Ltd. (hereinafter referred to as 'Minshi Pharmaceutical') stakeholders Tan Yunliang and Wang Zhong (hereinafter referred to as 'transferor'): due to reasons of the transferor, the transferor has decided to unilaterally terminate the cooperation with the company, terminate the 'Share Transfer Agreement' signed by both parties on February 28th, 2024, and promise to refund the transfer payment received from the company within 7 working days from the date of this notice. In view of the transferor's request to terminate the agreement due to unforeseen reasons, received...
No Data